Influences of levodopa on adipose tissue and skeletal muscle metabolism in patients with idiopathic Parkinson's disease

European Journal of Clinical Pharmacology

Volumn 64, Issue 9, 2008, Pages 863-870

  Adams, Frauke ^a,c   Boschmann, Michael ^a   Lobsien, Elmar ^a   Kupsch, Andreas ^a   Lipp, Axel ^a   Franke, Gabriele ^a   Leisse, Marie Charlotte ^a   Janke, Juergen ^a   Gottschalk, Simone ^a   Spranger, Joachim ^b   Jordan, Jens ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c FRANZ VOLHARD CLINIC   (Germany)

Author keywords

Adipose tissue; Lipolysis; Metabolism; Parkinson's disease; Skeletal muscle

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ALCOHOL; BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; GLUCOSE; GLYCEROL; LACTIC ACID; LEVODOPA; NORADRENALIN; PYRUVIC ACID;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; AGED; ARTICLE; CARBOHYDRATE METABOLISM; CELL ISOLATION; CLINICAL ARTICLE; DIALYSATE; FATTY ACID OXIDATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; IN VITRO STUDY; LIPID METABOLISM; LIPOLYSIS; MALE; MICRODIALYSIS; MUSCLE METABOLISM; NORADRENALIN BLOOD LEVEL; PARKINSON DISEASE; PRIORITY JOURNAL; SIDE EFFECT; SKELETAL MUSCLE; TISSUE BLOOD FLOW; WEIGHT REDUCTION;

ADIPOCYTES; ADIPOSE TISSUE; AGED; ANTIPARKINSON AGENTS; BENSERAZIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLYCEROL; HUMANS; ISOPROTERENOL; LEVODOPA; MALE; MICRODIALYSIS; MIDDLE AGED; MUSCLE, SKELETAL; PARKINSON DISEASE; REGIONAL BLOOD FLOW; SUBCUTANEOUS FAT;

EID: 50849118127     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0532-4     Document Type: Article

References (39)

1. HS Markus AM Tomkins GM Stern 1993 Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters J Neural Transm Parkinson's Dis Dement Sect 5 117 125
2. KN Davies D King H Davies 1994 A study of the nutritional status of elderly patients with Parkinson's disease Age Ageing 23 142 145
3. CG Bachmann C Trenkwalder 2006 Body weight in patients with Parkinson's disease Mov Disord 21 1824 1830
4. S Palhagen B Lorefalt M Carlsson 2005 Does L-dopa treatment contribute to reduction in body weight in elderly patients with Parkinson's disease? Acta Neurol Scand 111 12 20
5. MJ Toth PS Fishman ET Poehlman 1997 Free-living daily energy expenditure in patients with Parkinson's disease Neurology 48 88 91
6. RA Abbott M Cox H Markus 1992 Diet, body size and micronutrient status in Parkinson's disease Eur J Clin Nutr 46 879 884
7. B Lorefalt W Ganowiak S Palhagen 2004 Factors of importance for weight loss in elderly patients with Parkinson's disease Acta Neurol Scand 110 180 187
8. F Macia C Perlemoine I Coman 2004 Parkinson's disease patients with bilateral subthalamic deep brain stimulation gain weight Mov Disord 19 206 212
9. ML Giroux 2007 Parkinson disease: managing a complex, progressive disease at all stages Cleve Clin J Med 74 313 320
10. AE Boyd III HE Lebovitz JB Pfeiffer 1970 Stimulation of human-growth-hormone secretion by L-dopa N Engl J Med 283 1425 1429
11. CR Sirtori P Bolme DL Azarnoff 1972 Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism N Engl J Med 287 729 733
12. D Deleu S Sarre G Ebinger 1993 Simultaneous monitoring of levodopa, dopamine and their metabolites in skeletal muscle and subcutaneous tissue in different pharmacological conditions using microdialysis J Pharm Biomed Anal 11 577 585
13. N Pizzinat L Marti A Remaury 1999 High expression of monoamine oxidases in human white adipose tissue: evidence for their involvement in noradrenaline clearance Biochem Pharmacol 58 1735 1742
14. N Morin JM Lizcano E Fontana 2001 Semicarbazide-sensitive amine oxidase substrates stimulate glucose transport and inhibit lipolysis in human adipocytes J Pharmacol Exp Ther 297 563 572
15. F Adams M Boschmann K Schaller 2006 Tyramine in the assessment of regional adrenergic function Biochem Pharmacol 72 1724 1729
16. C Bairras C Ferrand C Atgie 2003 Effect of tyramine, a dietary amine, on glycerol and lactate release by isolated adipocytes from old rats J Physiol Biochem 59 161 167
17. M Boschmann G Krupp FC Luft 2002 In vivo response to alpha(1)- adrenoreceptor stimulation in human white adipose tissue Obes Res 10 555 558
18. J Jordan J Tank M Stoffels 2001 Interaction between beta-adrenergic receptor stimulation and nitric oxide release on tissue perfusion and metabolism J Clin Endocrinol Metab 86 2803 2810
19. MM Hoehn MD Yahr 1967 Parkinsonism: onset, progression and mortality Neurology 17 427 442
20. AJ Hughes Y Ben-Shlomo SE Daniel 1992 What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study Neurology 42 1142 1146
21. P Arner J Bolinder A Eliasson 1988 Microdialysis of adipose tissue and blood for in vivo lipolysis studies Am J Physiol 255 E737 E742
22. J Janke S Engeli K Gorzelniak 2002 Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors Diabetes 51 1699 1707
23. SK Han C Mytilineou G Cohen 1996 L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress J Neurochem 66 501 510
24. G Fellander B Linde J Bolinder 1996 Evaluation of the microdialysis ethanol technique for monitoring of subcutaneous adipose tissue blood flow in humans Int J Obes Relat Metab Disord 20 220 226
25. B Stallknecht J Lorentsen LH Enevoldsen 2001 Role of the sympathoadrenergic system in adipose tissue metabolism during exercise in humans J Physiol 536 283 294
26. A Kurpad K Khan AG Calder 1994 Effect of noradrenaline on glycerol turnover and lipolysis in the whole body and subcutaneous adipose tissue in humans in vivo Clin Sci 86 177 184
27. JL Smith JS Ju BM Saha 2004 Levodopa with carbidopa diminishes glycogen concentration, glycogen synthase activity, and insulin-stimulated glucose transport in rat skeletal muscle J Appl Physiol 97 2339 2346
28. JL Smith PB Patil SD Minteer 2005 Possibility of autocrine beta-adrenergic signaling in C2C12 myotubes Exp Biol Med 230 845 852
29. S Rose P Jenner CD Marsden 1988 The effect of carbidopa on plasma and muscle levels of L-dopa, dopamine, and their metabolites following L-dopa administration to rats Mov Disord 3 117 125
30. SW Coppack M Persson RL Judd 1999 Glycerol and nonesterified fatty acid metabolism in human muscle and adipose tissue in vivo Am J Physiol 276 E233 E240
31. RE Duncan M Ahmadian K Jaworski 2007 Regulation of lipolysis in adipocytes Annu Rev Nutr 27 79 101
32. N Mauras MW Haymond 2005 Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 15 19 27
33. L Hellström H Wahrenberg S Reynisdottir 1997 Catecholamine-induced adipocyte lipolysis in human hyperthyroidism J Clin Endocrinol Metab 82 159 166
34. N Dizdar A Kullman B Norlander 1999 Human pharmacokinetics of L-3,4-dihydroxyphenylalanine studied with microdialysis Clin Chem 45 1813 1820
35. V Visentin D Prevot L Marti 2003 Inhibition of rat fat cell lipolysis by monoamine oxidase and semicarbazide-sensitive amine oxidase substrates Eur J Pharmacol 466 235 243
36. J Lyytinen S Kaakkola S Ahtila 1997 Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson's disease Mov Disord 12 497 505
37. M Flechtner-Mors CP Jenkinson A Alt 2005 Studies of phosphodiesterase effects on adipose tissue metabolism in obese subjects by the microdialysis technique J Physiol Pharmacol 56 355 368
38. GH Goossens EE Blaak WH Saris 2004 Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects J Clin Endocrinol Metab 89 2690 2696
39. R Sandyk 1993 The relationship between diabetes mellitus and Parkinson's disease Int J Neurosci 69 125 130